05-29-07

PATENT APPLICATION

TATES PATENT AND TRADEMARK OFFICE

Applicant(s): Feige et al.

Serial No.:

10/645,784

Group Art Unit No.: 1639

Filed:

August 18, 2003

Examiner: Teresa D. Wessendorf

For:

MODIFIED PEPTIDES AS THERAPEUTIC AGENTS

Docket No.: A-527E

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form. Copies of the listed references are enclosed for consideration by the Examiner.

Applicants make no determination of relevancy with respect to the references submitted herewith and request the Examiner to make an independent determination of relevance and/or materiality of these references.

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last, but before the mailing date of a Notice of Allowance.

FEE PAYMENT

Please charge Deposit Account No. 01-0519 in the amount of \$180.00 (37 CFR 1.97(c)). An original and one copy are enclosed.

> 05/30/2007 NNGUYEN1 00000065 010519 10645784

01 FC:1806

180.00 DA

EXPRESS MAIL CERTIFICATE

Express Mail label number:

NEE DEE

EL 732697919 US

Date of Deposit: MAY 24, 2007

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" ser nmissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1

1

The Commissioner is hereby authorized to charge any additional fees that may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Timothy J. Gaul

Attorney/Agent for Applicant(s)
Registration No.: 33, 111

Phone: (805) 447-2688 Date: May 24, 2007

Please send all future correspondence to:

US Patent Operations/ TJG Dept. 4300, M/S 28-2-C AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799